Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors
by

1 Answer

Answer :

B. It is longer acting
by

Related questions

Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Description : Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Last Answer : B. It is longer acting

Pyridostigmine differs from neostigmine in that (a) More potent orally (b) Longer acting (c) Less muscarinic side effects (d) All of the above

Description : Pyridostigmine differs from neostigmine in that (a) More potent orally (b) Longer acting (c) Less muscarinic side effects (d) All of the above

Last Answer : Ans: B

Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Description : Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Last Answer : C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate

Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Description : Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Last Answer : A. Is a β1 selective blocker

Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Description : Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Last Answer : C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate

Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Description : Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Last Answer : C. It does not have antiandrogenic action

Cholinergic muscarinic receptor stimulation produces the following effects except: A. Sweating B. Rise in blood pressure C. Bradycardia D. Urination

Description : Cholinergic muscarinic receptor stimulation produces the following effects except: A. Sweating B. Rise in blood pressure C. Bradycardia D. Urination

Last Answer : B. Rise in blood pressure

Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Description : Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Last Answer : A. Is a β1 selective blocker

The cardiac muscarinic receptors: A. Are of the M1 subtype B. Are of the M2 subtype C. Are selectively blocked by pirenzepine D. Function through the PIP2 → IP3/DAG pathway

Description : The cardiac muscarinic receptors: A. Are of the M1 subtype B. Are of the M2 subtype C. Are selectively blocked by pirenzepine D. Function through the PIP2 → IP3/DAG pathway

Last Answer : B. Are of the M2 subtype

Muscarinic cholinergic receptors: A. Are located only on parasympathetically innervated effector cells B. Mediate responses by opening an intrinsic Na+ ion channel C. Are present on vascular endothelium which has no cholinergic nerve supply D. Predominate in the autonomic ganglia

Description : Muscarinic cholinergic receptors: A. Are located only on parasympathetically innervated effector cells B. Mediate responses by opening an intrinsic Na+ ion channel C. Are present on vascular endothelium which has no cholinergic nerve supply D. Predominate in the autonomic ganglia

Last Answer : C. Are present on vascular endothelium which has no cholinergic nerve supply

The mechanism by which neostigmine improves contraction of myasthenic muscle involves: A. Repetitive binding of the acetylcholine molecules to the same receptors at the muscle endplate B. Diffusion of acetylcholine released from motor nerve endings to a wider area activating neighbouring receptors C. Activation of motor end-plate receptors by neostigmine molecules themselves D. All of the above

Description : The mechanism by which neostigmine improves contraction of myasthenic muscle involves: A. Repetitive binding of the acetylcholine molecules to the same receptors at the muscle endplate B. Diffusion of ... Activation of motor end-plate receptors by neostigmine molecules themselves D. All of the above

Last Answer : D. All of the above

Hyoscine differs from atropine in that it (a) Exerts depressant effects on the CNS at relatively low doses (b) Exerts more potent effects on the heart than on the eye (c) Is longer acting (d) Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it (a) Exerts depressant effects on the CNS at relatively low doses (b) Exerts more potent effects on the heart than on the eye (c) Is longer acting (d) Has weaker antimotion sickness activity

Last Answer : Ans: A

Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Last Answer : A. Exerts depressant effects on the CNS at relatively low doses

Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Last Answer : A. Exerts depressant effects on the CNS at relatively low doses

The progestin used in combined oral contraceptive pill is a 19-nortestosterone derivative because: A. They have potent antiovulatory action of their own B. They do not produce any metabolic effects C. They produce fewer side effects D. They are longer acting

Description : The progestin used in combined oral contraceptive pill is a 19-nortestosterone derivative because: A. They have potent antiovulatory action of their own B. They do not produce any metabolic effects C. They produce fewer side effects D. They are longer acting

Last Answer : A. They have potent antiovulatory action of their own

Study of drug-receptor interaction has now shown that: A. Maximal response occurs only when all receptors are occupied by the drug B. Drugs exert an ‘all or none’ action on a receptor C. Receptor and drugs acting on it have rigid complementary ‘lock and key’ structural features D. Properties of ‘affinity’ and ‘intrinsic activity’ are independently variable

Description : Study of drug-receptor interaction has now shown that: A. Maximal response occurs only when all receptors are occupied by the drug B. Drugs exert an all or none' action on a ... lock and key' structural features D. Properties of affinity' and intrinsic activity' are independently variable

Last Answer : D. Properties of ‘affinity’ and ‘intrinsic activity’ are independently variable

Drugs acting through receptors exhibit the following features except: A. Structural specificity B. High potency C. Competitive antagonism D. Dependence of action on lipophilicity

Description : Drugs acting through receptors exhibit the following features except: A. Structural specificity B. High potency C. Competitive antagonism D. Dependence of action on lipophilicity

Last Answer : D. Dependence of action on lipophilicity

Study of drug-receptor interaction has now shown that: A. Maximal response occurs only when all receptors are occupied by the drug B. Drugs exert an ‘all or none’ action on a receptor C. Receptor and drugs acting on it have rigid complementary ‘lock and key’ structural features D. Properties of ‘affinity’ and ‘intrinsic activity’ are independently variable

Description : Study of drug-receptor interaction has now shown that: A. Maximal response occurs only when all receptors are occupied by the drug B. Drugs exert an all or none' action on a ... lock and key' structural features D. Properties of affinity' and intrinsic activity' are independently variable

Last Answer : D. Properties of ‘affinity’ and ‘intrinsic activity’ are independently variable

Drugs acting through receptors exhibit the following features except: A. Structural specificity B. High potency C. Competitive antagonism D. Dependence of action on lipophilicity

Description : Drugs acting through receptors exhibit the following features except: A. Structural specificity B. High potency C. Competitive antagonism D. Dependence of action on lipophilicity

Last Answer : D. Dependence of action on lipophilicity

he following is true of desmopressin except: A. It is nonselective V1 and V2 receptor agonist B. It is more potent and longer acting than arginine vasopressin (AVP) C. It is preferred over AVP for treatment of diabetes insipidus D. It can be administered orally

Description : Che following is true of desmopressin except: A. It is nonselective V1 and V2 receptor agonist B. It is more potent and longer acting than arginine vasopressin (AVP) C. It is preferred over AVP for treatment of diabetes insipidus D. It can be administered orally

Last Answer : A. It is nonselective V1 and V2 receptor agonist

Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Description : Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Last Answer : D. Both 'B' and 'C' are correct

Timolol eye drops are preferred over pilocarpine eye drops by glaucoma patients because: A. Timolol is more effective than pilocarpine B. Timolol acts by enhancing uveo-scleral outflow C. Timolol produces less ocular side effects D. There are no contraindications to timolol

Description : Timolol eye drops are preferred over pilocarpine eye drops by glaucoma patients because: A. Timolol is more effective than pilocarpine B. Timolol acts by enhancing uveo-scleral outflow C. Timolol produces less ocular side effects D. There are no contraindications to timolol

Last Answer : C. Timolol produces less ocular side effects

Which of the following is a relatively cerebroselective anticholinesterase found to afford symptomatic improvement in Alzheimer's disease: A. Donepezil B. Gemfibrozil C. Pyridostigmine D. Pyritinol

Description : Which of the following is a relatively cerebroselective anticholinesterase found to afford symptomatic improvement in Alzheimer's disease: A. Donepezil B. Gemfibrozil C. Pyridostigmine D. Pyritinol

Last Answer : A. Donepezil

riiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action

Description : riiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action

Last Answer : B. It has a shorter plasma half life

17.2 Triiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action (

Description : 17.2 Triiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action (

Last Answer : B. It has a shorter plasma half life

Dexamethasone differs from prednisolone in that it is: A. Longer acting B. More potent C. More selective D. All of the above

Description : Dexamethasone differs from prednisolone in that it is: A. Longer acting B. More potent C. More selective D. All of the above

Last Answer : D. All of the above

Out of two anticholinesterases, drug ‘X’ is a tertiary amine while drug ‘Y’ is a quarternary ammonium compound. Then: A. Drug ‘X’ is likely to be more potent than ‘Y’ B. Drug ‘X’ will be more suitable to be used as a miotic C. Drug ‘Y’ will be completely metabolized in the body D. Drug ‘Y’ will produce CNS effects

Description : Out of two anticholinesterases, drug X' is a tertiary amine while drug Y' is a quarternary ammonium compound. Then: A. Drug X' is likely to be more potent than Y' B. Drug X' will be more ... a miotic C. Drug Y' will be completely metabolized in the body D. Drug Y' will produce CNS effects

Last Answer : B. Drug ‘X’ will be more suitable to be used as a miotic

Edrophonium is more suitable for differentiating myasthenic crisis from cholinergic crisis because of its: A. Shorter duration of action B. Longer duration of action C. Direct action on muscle end-plate D. Selective inhibition of true cholinesterase

Description : Edrophonium is more suitable for differentiating myasthenic crisis from cholinergic crisis because of its: A. Shorter duration of action B. Longer duration of action C. Direct action on muscle end-plate D. Selective inhibition of true cholinesterase

Last Answer : A. Shorter duration of action

In congestive heart failure patients: A. Volume of distribution of all drugs is increased B. Hepatic clearance of drugs is unaffected C. Orally administered diuretics may not be effective, but the same may work parenterally D. Inotropic action of digoxin is attenuated

Description : In congestive heart failure patients: A. Volume of distribution of all drugs is increased B. Hepatic clearance of drugs is unaffected C. Orally administered diuretics may not be effective, but the same may work parenterally D. Inotropic action of digoxin is attenuated

Last Answer : C. Orally administered diuretics may not be effective, but the same may work parenterally

In congestive heart failure patients: A. Volume of distribution of all drugs is increased B. Hepatic clearance of drugs is unaffected C. Orally administered diuretics may not be effective, but the same may work parenterally D. Inotropic action of digoxin is attenuated

Description : In congestive heart failure patients: A. Volume of distribution of all drugs is increased B. Hepatic clearance of drugs is unaffected C. Orally administered diuretics may not be effective, but the same may work parenterally D. Inotropic action of digoxin is attenuated

Last Answer : C. Orally administered diuretics may not be effective, but the same may work parenterally

In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of action C. It activates dopamine D2 receptors, with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Description : In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of ... with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Last Answer : D. It does not produce behavioral/psychiatric side effects

Enalapril differs from captopril in the following features except: A. It is dose to dose more potent B. Its oral absorption is not affected by food in stomach C. It acts more rapidly D. It has longer duration of action

Description : Enalapril differs from captopril in the following features except: A. It is dose to dose more potent B. Its oral absorption is not affected by food in stomach C. It acts more rapidly D. It has longer duration of action

Last Answer : D. Lisinopri

The antagonism between adrenaline and histamine is called ‘physiological antagonism’ because: A. Both are physiologically present in the body B. They act on physiological receptors C. Both affect many physiological processes D. They have opposite physiological effects

Description : The antagonism between adrenaline and histamine is called ‘physiological antagonism’ because: A. Both are physiologically present in the body B. They act on physiological receptors C. Both affect many physiological processes D. They have opposite physiological effects

Last Answer : D. They have opposite physiological effects

The antagonism between adrenaline and histamine is called ‘physiological antagonism’ because: A. Both are physiologically present in the body B. They act on physiological receptors C. Both affect many physiological processes D. They have opposite physiological effects

Description : The antagonism between adrenaline and histamine is called ‘physiological antagonism’ because: A. Both are physiologically present in the body B. They act on physiological receptors C. Both affect many physiological processes D. They have opposite physiological effects

Last Answer : D. They have opposite physiological effects

Which of the following is a G protein coupled receptor: A. Muscarinic cholinergic receptor B. Nicotinic cholinergic receptor C. Glucocorticoid receptor D. Insulin receptor

Description : Which of the following is a G protein coupled receptor: A. Muscarinic cholinergic receptor B. Nicotinic cholinergic receptor C. Glucocorticoid receptor D. Insulin receptor

Last Answer : A. Muscarinic cholinergic receptor

A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Description : A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Last Answer : B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication

A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Description : A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Last Answer : B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication

Reactivation of cholinesterase enzyme occurs on hydrolysis of the inhibitor by the same enzyme molecule in case of the following anticholinesterase: A. Edrophonium B. Neostigmine C. Dyflos D. Tacrine

Description : Reactivation of cholinesterase enzyme occurs on hydrolysis of the inhibitor by the same enzyme molecule in case of the following anticholinesterase: A. Edrophonium B. Neostigmine C. Dyflos D. Tacrine

Last Answer : B. Neostigmine

The following inhibitor binds only to the ani-onic site of the cholinesterase enzyme: A. Neostigmine B. Physostigmine C. Edrophonium D. Dyflos

Description : The following inhibitor binds only to the ani-onic site of the cholinesterase enzyme: A. Neostigmine B. Physostigmine C. Edrophonium D. Dyflos

Last Answer : C. Edrophonium

Select the longer acting ocular beta blocker: A. Timolol B. Betaxolol C. Cartiolol D. Levobunolol

Description : Select the longer acting ocular beta blocker: A. Timolol B. Betaxolol C. Cartiolol D. Levobunolol

Last Answer : D. Levobunolol

Olanzapine has the following features except: A. It is an antipsychotic drug with weak D2 receptor blocking action B. It has potent 5-HT2 blocking and antimuscarinic actions C. It lowers seizure threshold D. It produces prominent extrapyramidal side effects

Description : Olanzapine has the following features except: A. It is an antipsychotic drug with weak D2 receptor blocking action B. It has potent 5-HT2 blocking and antimuscarinic actions C. It lowers seizure threshold D. It produces prominent extrapyramidal side effects

Last Answer : D. It produces prominent extrapyramidal side effect

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Fluconazole differs from ketoconazole in that: A. It is not active by the oral route B. It is a more potent inhibitor of drug metabolism C. It is not effective in cryptococcal meningitis D. It is unlikely to produce anti-androgenic side effects

Description : Fluconazole differs from ketoconazole in that: A. It is not active by the oral route B. It is a more potent inhibitor of drug metabolism C. It is not effective in cryptococcal meningitis D. It is unlikely to produce anti-androgenic side effects

Last Answer : D. It is unlikely to produce anti-androgenic side effects

Enalapril differs from captopril in that: A. It blocks angiotensin II receptors B. It does not produce cough as a side effect C. It is less liable to cause abrupt first dose hypotension D. It has a shorter duration of action

Description : Enalapril differs from captopril in that: A. It blocks angiotensin II receptors B. It does not produce cough as a side effect C. It is less liable to cause abrupt first dose hypotension D. It has a shorter duration of action

Last Answer : C. It is less liable to cause abrupt first dose hypotension

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Tricyclic antidepressants can alter the oral absorption of many drugs by: A. Complexing with the other drug in the intestinal lumen B. Altering gut motility C. Altering gut flora D. Damaging gut mucosa

Last Answer : C. Altering gut flora

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to ... in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Last Answer : A. Percentage of administered dose that reaches systemic circulation in the unchanged form

Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to that excreted in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Description : Bioavailability of drug refers to: A. Percentage of administered dose that reaches systemic circulation in the unchanged form B. Ratio of oral to parenteral dose C. Ratio of orally administered drug to ... in the faeces D. Ratio of drug excreted unchanged in urine to that excreted as metabolites

Last Answer : A. Percentage of administered dose that reaches systemic circulation in the unchanged form

Fluconazole offers the following advantage(s) over ketoconazole: A. It is longer acting B. Its absorption from stomach is not dependent on gastric acidity C. It produces fewer side effects D. All of the above

Description : Fluconazole offers the following advantage(s) over ketoconazole: A. It is longer acting B. Its absorption from stomach is not dependent on gastric acidity C. It produces fewer side effects D. All of the above

Last Answer : D. All of the above

Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Description : Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Last Answer : D. A more potent drug can produce the same response at lower doses

Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Description : Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Last Answer : D. A more potent drug can produce the same response at lower doses